These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 32098021)

  • 1. Antioxidants as a Potential Target against Inflammation and Oxidative Stress in Attention-Deficit/Hyperactivity Disorder.
    Alvarez-Arellano L; González-García N; Salazar-García M; Corona JC
    Antioxidants (Basel); 2020 Feb; 9(2):. PubMed ID: 32098021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Oxidative Stress and Neuroinflammation in Attention-Deficit/Hyperactivity Disorder.
    Corona JC
    Antioxidants (Basel); 2020 Oct; 9(11):. PubMed ID: 33114154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale for Dietary Antioxidant Treatment of ADHD.
    Verlaet AAJ; Maasakkers CM; Hermans N; Savelkoul HFJ
    Nutrients; 2018 Mar; 10(4):. PubMed ID: 29587355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natural Compounds for the Management of Parkinson's Disease and Attention-Deficit/Hyperactivity Disorder.
    Corona JC
    Biomed Res Int; 2018; 2018():4067597. PubMed ID: 30596091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitamin D's Molecular Action Mechanism in Attention-Deficit/ Hyperactivity Disorder: A Review of Evidence.
    Saedisomeolia A; Samadi M; Gholami F; Seyedi M; Effatpanah M; Hashemi R; Abdolahi M; Honarvar NM
    CNS Neurol Disord Drug Targets; 2018; 17(4):280-290. PubMed ID: 29714151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxidative and nitrosative stress in ADHD: possible causes and the potential of antioxidant-targeted therapies.
    Lopresti AL
    Atten Defic Hyperact Disord; 2015 Dec; 7(4):237-47. PubMed ID: 25894292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of total oxidative status in adult attention deficit hyperactivity disorder and its diagnostic implications.
    Selek S; Bulut M; Ocak AR; Kalenderoğlu A; Savaş HA
    J Psychiatr Res; 2012 Apr; 46(4):451-5. PubMed ID: 22257388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased oxidative stress in children with attention deficit hyperactivity disorder.
    Sezen H; Kandemir H; Savik E; Basmacı Kandemir S; Kilicaslan F; Bilinc H; Aksoy N
    Redox Rep; 2016 Nov; 21(6):248-53. PubMed ID: 26886057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention Deficit Hyperactivity Disorder and oxidative stress: A short term follow up study.
    Guney E; Cetin FH; Alisik M; Tunca H; Tas Torun Y; Iseri E; Isik Taner Y; Cayci B; Erel O
    Psychiatry Res; 2015 Sep; 229(1-2):310-7. PubMed ID: 26188640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder.
    Curtin K; Fleckenstein AE; Keeshin BR; Yurgelun-Todd DA; Renshaw PF; Smith KR; Hanson GR
    Neuropsychopharmacology; 2018 Dec; 43(13):2548-2555. PubMed ID: 30209407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Review on the Role of Inflammation in Attention-Deficit/Hyperactivity Disorder.
    Leffa DT; Torres ILS; Rohde LA
    Neuroimmunomodulation; 2018; 25(5-6):328-333. PubMed ID: 29874674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of the pathophysiology, etiology, and treatment of attention-deficit hyperactivity disorder (ADHD).
    Sharma A; Couture J
    Ann Pharmacother; 2014 Feb; 48(2):209-25. PubMed ID: 24259638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative Stress and ADHD: A Meta-Analysis.
    Joseph N; Zhang-James Y; Perl A; Faraone SV
    J Atten Disord; 2015 Nov; 19(11):915-24. PubMed ID: 24232168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and treatment of attention deficit hyperactivity disorder (ADHD).
    NIH Consens Statement; 1998 Nov 16-18; 16(2):1-37. PubMed ID: 10868163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD).
    Kollins SH
    Am J Addict; 2007; 16 Suppl 1():35-42; quiz 43-4. PubMed ID: 17453605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of n-3 supplementation on hyperactivity, oxidative stress and inflammatory mediators in children with attention-deficit-hyperactivity disorder.
    Hariri M; Djazayery A; Djalali M; Saedisomeolia A; Rahimi A; Abdolahian E
    Malays J Nutr; 2012 Dec; 18(3):329-35. PubMed ID: 24568073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid peroxidation markers in adult attention deficit hyperactivity disorder: new findings for oxidative stress.
    Bulut M; Selek S; Bez Y; Cemal Kaya M; Gunes M; Karababa F; Celik H; Savas HA
    Psychiatry Res; 2013 Oct; 209(3):638-42. PubMed ID: 23680468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interactions among organophosphate pesticide exposure, oxidative stress, and genetic polymorphisms of dopamine receptor D4 increase the risk of attention deficit/hyperactivity disorder in children.
    Chang CH; Yu CJ; Du JC; Chiou HC; Chen HC; Yang W; Chung MY; Chen YS; Hwang B; Mao IF; Chen ML
    Environ Res; 2018 Jan; 160():339-346. PubMed ID: 29054088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.